Kornimate/medical-research-clean huggingface dataset:
spine rehabilitation using spine flexion / extension full active range of motion for patients with chronic low back pain

Conditions: Low Back Pain

Summary: the main objective of this study is to assess efficacy of a spine rehabilitation program, using spine flexion and extension full active range of motion, on physical disability of patients with chronic low back pain.

secondary objectives the other objectives of this study are to assess the impact of spine rehabiliation program using spine flexion and extension full active range of motion on : * pain intensity ; * kinesiophobia * active range of motion of lumbar flexion and lumbar extension conduct of research after receiving the written consent of the study, participants will benefit from 5 sessions of spine flexion and extension full active range of motion exercises. the following tests and questionnaires will be performed before (baseline) and after (posttreatment) the 5 sessions : * visual analogue pain scale, * fear avoidance beliefs questionnaire (fabq), * double-inclinometer to measure active range of motion of lumbar flexion and lumbar extension.

Eligibility criteria:
inclusion criteria: * medical prescription for chronic low back pain rehabilitation * evolution of low back pain for at least 3 months * no treatment or rehabilitation for low back pain performed within 12 months before enrollment * written informed consent given exclusion criteria: * spinal fracture or previous spinal surgery * cognitive impairments that prevent from understanding the rehabilitation exercises * patient with insufficient understanding or expression in french * non-mechanical pain : gradually worsening pain, present at rest and especially at night * neurological symptom : deficit in the control of bladder and anal sphincters, motor weakness of lower limbs, cauda equina syndrome * pubis paresthesia (or perineum) * severe trauma (such as fall from height, traffic accident) * unexplained weight loss * history of cancer * drug use or long-term use of corticosteroid * spinal deformity * altered general condition * patient with signs of neurological impairment : positive lasegue test (straight leg raise test) or positive slump test, or dn4 questionnaire greater than or equal to 4 * patient suffering from a central or peripheral neurological pathology * patient taking a level ii (weak opiates) or iii (morphine and related substances) analgesic treatment * patient under guardianship, curatorship or legal protection

Keywords: rehabilitation active range of motion kinesiophobia physiotherapy
pd-1 knockout engineered t cells for castration resistant prostate cancer

Conditions: Hormone Refractory Prostate Cancer

Summary: this study will evaluate the safety of pd-1 knockout engineered t cells in treating castration resistant prostate cancer (crpc). blood samples will also be collected for research purposes.

this is a dose-escalation study of ex-vivo knocked-out, expanded, and selected pd-1 knockout-t cells from autologous origin. patients are assigned to 1 of 3 treatment groups to determine the maximal tolerant dose. after the lower number of cycles are considered tolerant, an arm of the next higher number of cycles will be open to next patients. biomarkers and immunological markers are collected and analyzed as well.

Eligibility criteria:
inclusion criteria: * pathologically and clinical verified castration resistant prostate cancer with measurable lesions (on ct: longest diameter of tumoral lesion \>=10 mm, shorted diameter of lymph node \>=15 mm; measurable lesions should not have been irradiated) * progressed after all standard treatment * performance score: 0-1 * expected life span: \>= 6 months * toxicities from prior treatment has resolved. washout period is 4 weeks for chemotherapy, and 2 weeks for targeted therapy * major organs function normally * willing and able to provide informed consent exclusion criteria: * pathology is mixed type * emergent treatment of tumor emergency is needed * poor vasculature * coagulopathy, or ongoing thrombolytics and/or anticoagulation * blood-borne infectious disease, e.g. hepatitis b * history of mandatory custody because of psychosis or other psychological disease inappropriate for treatment deemed by treating physician * with other immune diseases, or chronic use of immunosuppressants or steroids * compliance cannot be expected * other conditions requiring exclusion deemed by physician
osseointegration of hydroxyapatite-coated femoral stems in femoral neck fractures over 80 years

Conditions: Femoral Neck Fractures

Summary: this study aimes to prove that osseointegration of hydroxyapatite coated stem is possible for patients over 80 years with femoral neck fracture, without the risks of cemented stems. the hydroxyapatite has a local effect which can improve cortical index.


Eligibility criteria:
inclusion criteria: * 80 years * 1 year follow-up * femoral neck fracture exclusion criteria: * bad-realized radiographs
doppler ultrasound and ct versus laparoscopy in assessment of ovarian malignancy

Conditions: Ovarian Cancer

Summary: the aim of this study is to assess validation of ultrasound (± doppler) parameters in the diagnosis of suspicious ovarian malignant tumors and laparoscopic assessment of these findings according to fagotti score evaluation of suspicious malignant tumors

the aim of this study is to asses validation of ultrasound (± doppler) parameters in the diagnosis of suspicious ovarian malignant tumors and laparoscopic assessment of these findings according to fagotti score evaluation of suspicious malignant tumors

Eligibility criteria:
inclusion criteria: 1. all patients with clinical or radiological suspicion of ovarian cancer. 2. at least one of clinical presentation of suspected or advanced ovarian cancer and performed ultrasound or ct or mri that detect a pelvic mass and ca125 is more than 200 ul/ml. 3. patients with eastern cooperative oncology group status from 0 to 3. exclusion criteria: 1. the women outside the age group in our study. 2. any known malignancy at other sites. 3. uncompliant patients who have severed uncontrolled infection or any other medical problem. 4. any previous major surgery. 5. patients who refuse to give an informed consent to do laparoscopy. 6. pregnancy and its complications.

Keywords: ovarian cancer, doppler, ct, laparoscopy
comparing a new technique of combining carbon-dioxide with electrocautery with usual technique of stand-alone electrocautery for taking down left internal mammary artery for coronary artery bypass(cabg)

Conditions: Coronary Artery Disease; Coronary Artery Disease With Myocardial Infarction

Summary: the goal of this study is to compare the efficacy of a new harvesting technique for an arterial conduit(lima - left internal mammary artery) in patients undergoing coronary artery bypass grafting. the researcher will compare the 1. time taken to harvest the artery 2. flow of blood between the two techniques

following consultation to our department, after a detailed history and clinical examination,patients with cad, being planned for cabg, will be subjected to a detailed pre-op echocardiogram and coronary angiogram. after necessary pre-op assessment, patient will be taken up for the surgery. invasive monitoring will be done. following dissection of lima by the above mentioned technique, flow of blood from the harvested lima, for one whole minute is noted. the operative time required for the dissection of lima will be noted and entered. the data between the two techniques will be compared statistically.

Eligibility criteria:
inclusion criteria: 1. elective cabg 2. hemodynamically stable cad patients exclusion criteria: 1. re-operation, previous sternotomy (where lima is already dissected) 2. concomitant valve operation, ventricular aneurysm resection 3. other additional major cardiac procedures 4. patients with chronic obstructive pulmonary disease

Keywords: cabg, lima harvesting, cad
safety and clinical efficacy of local topical treatment for erectile dysfunction

Conditions: Erectile Dysfunction

Summary: vl#fia3-30 is a preparation intended for topical use, applied on the penis, for the treatment of ed.

vasolead's preparation to treat erectile dysfunction (ed), vl#fia3-30, is composed of 2 active pharmaceutical ingredients, both act as vasodilators via different mechanisms. both are currently used orally in the usa and europe for the treatment of hypertension, angina pectoris and other diseases.

Eligibility criteria:
inclusion criteria: * signed written informed consent. * ed for more than six months in duration. * iief-ef domain score at baseline from 11 to 19 . * willingness for a minimum of two sexual attempts during the short period of this study. * at least 50% unsuccessful sexual intercourse for 4 attempts on 4 different days. * a stable heterosexual relationship with the same partner for more than six months. * age 25 to 75 years old. exclusion criteria: * neurological pathology; * prior radical prostatectomy; * any unstable medical or psychiatric condition, spinal cord injury, or penile anatomical abnormalities; * clinically significant chronic hematological disease; * cardiovascular conditions that prevent sexual activity (chf or severe coronary artery disease); * history of myocardial infarction, stroke, or life-threatening arrhythmia within 6 months prior to enrollment into the study; * use of anti-androgens, or oral or injectable androgens; * documented hypotension (bp below 100 systolic or 70 diastolic) or known orthostatic hypotension; * routine use of more than 2 antihypertensive medications; * use of oral nitrates within 3 months prior to enrollment into the study; * cancer within the last 3 years; * documented allergic reaction; * investigators impression for patient non-compliance; * hepatic or renal failure; * history of hiv, hepatitis b, hepatitis c; * is an immediate family member of personnel directly affiliated with the study at the investigative site, or is personally directly affiliated with the study at the investigative site; * subject has taken any investigational medication within 30 days prior of entry into the study * employed by vasolead (2012) ltd.
study of onabotulinumtoxina (botox®) for urinary incontinence due to neurogenic detrusor overactivity in pediatric patients

Conditions: Urinary Incontinence

Summary: this study will evaluate the 3 doses of onabotulinumtoxina (botulinum toxin type a) for the treatment of urinary incontinence due to neurogenic detrusor overactivity in pediatric participants between the ages of 5 to 17 years to determine if 1 or more doses were safe and effective.


Eligibility criteria:
inclusion criteria: * urinary incontinence due to neurogenic detrusor overactivity * regularly using clean intermittent catheterization to empty the bladder exclusion criteria: * surgery of the spinal cord within 6 months * diagnosis of cerebral palsy * current or planned use of a baclofen pump * current or planned use of an electrostimulation/neuromodulation device for urinary incontinence * use of an indwelling catheter for urinary incontinence instead of using clean intermittent catheterization to empty the bladder * previous or current use of botulinum toxin therapy of any serotype for any urological condition, or treatment with botulinum toxin of any serotype within 3 months for any other condition or use * myasthenia gravis, eaton-lambert syndrome, or amyotrophic lateral sclerosis
the place of men in arrested pregnancies

Conditions: Arrested Pregnancies

Summary: an terminated pregnancy is defined as the cessation of cardiac activity before 14 weeks of amenorrhea. this early interruption of gestation can be induced by pathological, traumatic or idiopathic causes. in any case, it remains a physically and psychologically trying event for the woman, the couple as well as for the man. indeed, the loss of this embryo, which measures only a few millimeters, corresponds to the loss of a child for the triad: woman, man, couple. the termination of this pregnancy is experienced as a bereavement for the future parents. the stopped pregnancy has always been a taboo in the society. the proof being that it was not until the 1980s that this was considered mourning and its psychological consequences were studied. following these studies, psychological follow-ups are democratized and are thus offered to women. however, when is it men? the investigators have always put the woman at the center of the care process. which is legitimate. however, the man is often seen as "the person who influences the woman". this default categorization marginalizes the man who would like to be an actor in the care of his partner. in fact, men are increasingly asking to support women in their gynecological care procedures. unfortunately, for lack of measures put in place. the men are more than abandoned.


Eligibility criteria:
inclusion criteria: * age ≥18 years old * male * speaking french * the progenitor of the pregnancy and whose partner is affected by an aborted pregnancy exclusion criteria: * subject having expressed opposition to participating in the study * subject under safeguard of justice * subject under guardianship or guardianship * subject under guardianship, curatorship or safeguard of justice

Keywords: arrested pregnancies cardiac arrest
dosimetry and biodistribution of [18f]-fludarabine in lymphoid malignancies

Conditions: Untreated B-Chronic Lymphocytic Leukemia or Diffuse Large B Cells Lymphoma Patients

Summary: the application of positron emission tomography with lymphoproliferative diseases today provides diagnostic and therapeutic information of major importance , especially in terms of speed and quality of response to treatment. the radiopharmaceutical used in clinical practice for this exam is fluorodeoxyglucose 18f-2-fluoro-2-deoxy-d-glucose fluorodeoxyglucose (\[18f\]-fdg) . however , the uptake of this tracer is not elective in lymphoid tissues , with a lack of specificity. in addition , the avidity of this tracer is unequal according to the histological subtype (lack of sensitivity). to try to improve the results of this clinical exploration of lymphoid malignancies, the investigators developed a new radiopharmaceutical ( \[18f\] - fludarabine ). the idea of transforming the fludarabine radiopharmaceutical is based on the existence of a fluorine atom in the molecule and the pharmacokinetic characteristics of this drug. the \[18f\]-fludarabine is a new radiopharmaceutical reproducing the same dosage formulation of fludarabine , a drug used for the treatment of certain types of lymphoproliferative diseases, especially those where the tumor cells have a low proliferation kinetics . this drug is used in therapy in particular pharmacokinetic effect for a high affinity for the lymphoid tissue . preclinical results on normal and lymphoma xenograft -bearing mice showed a specificity restricted to lymphoid tissue fixation with \[18f\]-fludarabine compared with \[18f\]-fdg . based on these encouraging results , the investigators propose in this work to explore the dosimetry and biodistribution of \[18f\] - fludarabine in human lymphoproliferative diseases : 1)a first group of patients with non-hodgkin's large cell lymphomas in which it already has a wealth of experience in exploration \[18f\]-fdg, and 2) a second group of patients with chronic lymphocytic leukemia, where the results of the exploration \[18f\]-fdg are considered disappointing and did not, for this reason, experienced clinical development.


Eligibility criteria:
inclusion criteria: * adult over 18 * signed written informed consent * untreated stage b or c chronic lymphocytic leukemia * untreated diffuse large b-cell lymphoma * eligible for pet-ct * the subject must be covered by a social security system exclusion criteria: * age under 18 * patients concurrently included in an investigational trial * weight over 120 kg * pregnant women * active infectious disease * immune hemolytic anemia * patients with creatinine clearance \< 30 ml/mn * corticosteroid therapy

Keywords: pet chronic lymphocytic leukemia (cll) diffuse large b cells lymphoma (dlbcl) fludarabine
evaluation of a brief, scalable module to mitigate suicidal ideation among youth

Conditions: Suicidal Ideation

Summary: this project is designed to test a brief therapy to reduce suicidal ideation among a diverse sample of youths ages 12 to 17 who experience anxiety or depression. the goal of the study is to conduct a clinical trial testing whether this therapy reduces suicidal ideation and related beliefs that one is a burden on others. this project will contribute to the field by potentially showing evidence supportive of a brief strategy to reduce suicidal ideation in a way that can be readily understood and used by mental health providers in the community.

this project tests the ability of a brief therapy module to engage youth perceived burdensomeness (pb) in a rigorous randomized controlled trial (rct) of the intervention, the \&#34;give to others (go)\&#34; module. the investigators will target pb among 60 ethnically/racially diverse clinic-referred youths (ages 12-17) who experience subacute suicide ideation si (i.e., positive suicide risk screen; stable safety status). youths will be recruited from the clinical and community settings and will be randomized to one of the following 2 arms: an assessment and suicide risk management condition (safety planning control arm); and a safety planning plus go module condition. the investigators hypothesize that youths receiving the go module will have lower levels of pb at post-treatment compared with youths who receive the control arm. the investigators also hypothesize that youths receiving the go module will have lower levels of pb at post-treatment compared to pre-treatment levels.

Eligibility criteria:
inclusion criteria adolescents must: * be between ages 12 and 17 years * score at or above 4 on the interpersonal needs questionnaire- burdensomeness scale * have a positive screen for suicide risk (i.e., endorsement of suicidal ideation via self-report or parent-report). exclusion criteria for adolescents to be excluded, they must: * have cognitive impairment or developmental delay which does not allow for the completion of basic study procedures (i.e., reading and filling out questionnaires; talking to a clinician) * show imminent risk or a history of hurting themselves or others requiring intensive and restrictive services * be involved currently in a psychosocial treatment
assessment of brain activities in cervical dystonia

Conditions: Cervical Dystonia

Summary: to address joint position sense in cervical dystonia patients and how it affects the brain activity.


Eligibility criteria:
inclusion criteria: * patients having cervical dystonia and aged matched healthy control group exclusion criteria: * cervical dystonia patients with severe head tremor will be excluded
gabapentin as adjunctive treatment for postoperative pain control

Conditions: Drug Usage

Summary: the specific aims of this research study are to use 600 mg gabapentin as an adjunctive treatment for acute postoperative pain control in order to reduce postoperative opiate consumption and improve postoperative pain control.

after consent has been obtained for the study and the cesarean has been completed, when the participant is in the recovery room, she will take the first pill of the study drug. this will occur approximately 30-60 minutes after the cesarean is completed. the time of first dose will be noted on the data capture form. the following will then occur: * participants will take study capsules (either 600 mg gabapentin or placebo) every 8 hours for the first 48 hours after beginning the study. the nurse on the unit will be sent the study drug in a blinded capsule by the investigational pharmacy. * participants will be asked about postoperative pain on a visual analog scale by the care nurses or study personnel before each dose of study drug, before receiving any opioid medication, 2-4 hours after study drugs are consumed, at 24, 36 and 48 hours post surgery, and any other times during routine postoperative clinical care would warrant. women record pain postoperatively on a similar scale as part of routine clinical care. prescription pain medication will be given per clinical routine care. study personnel will note how many pills were sent home. * one week (6-9 days) after the cesarean delivery, participants will be contacted by phone or other preferred method and asked about pain score, somnolence scores, dizziness, nausea, depression, any problems they are experiencing, and asked how many pain pills are left in their prescriptions given when they went home. these data will be recorded. an edinburgh depression scale will also be administered upon consent, at 48 hours, and again at one week after delivery. if the scores meet the specified criteria, the provider will by notified or if the subject has already been discharged from the hospital, she will be given contact information for follow up care.

Eligibility criteria:
inclusion criteria: * pregnant women at least 18 years of age * singleton gestation * gestational age equal to or greater than 30 weeks * women undergoing a non-emergent (often scheduled) repeat cesarean delivery * spinal anesthesia utilized during cesarean exclusion criteria: * history of opiate abuse * women on opiates during pregnancy * women requiring treatment with magnesium sulfate postpartum * preexisting fibromyalgia, chronic pain syndrome, or rheumatologic disorder * general anesthesia required for cesarean * plans to breastfeed * history of major depression or postpartum depression requiring medication * planned classical cesarean section

Keywords: gabapentin
the use of a forecasting system for predicting exacerbations of copd

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: people with chronic obstructive pulmonary disease (copd) often have periods during the year when their symptoms become worse. these are often due to an infection and are called "exacerbations" by doctors. exacerbations are more common in the winter and also seem to be related to particular types of weather. as well as forecasting the weather the uk met office has developed a system to try to predict when exacerbations are likely to occur. the main purpose of this research study is to find out whether the met office forecasting service can predict when exacerbations are more likely to occur and whether the advice given during the predicted higher risk periods leads to fewer patients having an exacerbation or if it reduces the impact of the exacerbation. the study will also assess if there is a link between viral or bacterial infection and breathing problems that occur during the study period. the study will also collect information about possible causes of the breathing problems and what happens to the person afterwards. the results of this study will help us learn more about breathing problems which may lead to new research studies that would aim to improve the care of people with copd.


Eligibility criteria:
inclusion criteria: * current or former smokers with a diagnosis of copd * having impaired lung function as measured by spirometry exclusion criteria: * history of asthma or nasal symptoms caused by hayfever * no telephone * inability to record symptoms in an electronic diary (pda)

Keywords: smoking copd chronic obstructive lung disease copd exacerbations viruses and bacteria associated with copd exacerbations